Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Table 3

Secondary endpoint-a occurrences (all cardiovascular events, SBIs and adverse events).

	ASA n=36	controls n=47
	n (%)	n (%)	p-value (Chi-Square)
Non-fatal stroke	1 (2.8)	1 (2.1)	0.331
TIA	-	1 (2.1)
New SBIs	1 (2.8)	6 (12.8)
Non-fatal MI	2 (5.6)	1 (2.1)
CV mortality	-	1 (2.1)
Gastrointestinal adverse events	2 (5.6)	1 (2.1)
Epistaxis	-	1 (2.1)
Other causes of mortality	-	-
No events	30 (83.3)	35 (74.5)